Evidence map›Paper›PMID 39315734›Full record

ArticleCancer medicine2024

Angiogenesis and multiple myeloma: Exploring prognostic potential of adrenomedullin.

Angelos Giannakoulas, Panagiotis Stoikos, Evangelia Kouvata, Katerina M Kontouli, Georgios Fotiadis, Georgia Stefani, Grigorios D Amoutzias, George Vassilopoulos, Nikolaos Giannakoulas

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Adrenomedullin in Tumorigenesis and Cancer Progression.International journal of molecular sciences · 2025
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Angelos GiannakoulasLaboratory of Hematology Department, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Panagiotis StoikosLaboratory of Hematology Department, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Evangelia KouvataHematology Department, University Hospital of Larissa, Larissa, Greece.
Katerina M KontouliLaboratory of Hygiene and Epidemiology, Faculty of Medicine, University of Thessaly, Larissa, Greece.
Georgios FotiadisHematology Department, University Hospital of Larissa, Larissa, Greece.
Georgia StefaniHematology Department, University Hospital of Larissa, Larissa, Greece.
Grigorios D AmoutziasBioinformatics Laboratory, Department of Biochemistry & Biotechnology, School of Health Sciences, University of Thessaly, Larissa, Greece.
George VassilopoulosHematology Department, University Hospital of Larissa, Larissa, Greece.
Nikolaos GiannakoulasHematology Department, University Hospital of Larissa, Larissa, Greece.ORCID https://orcid.org/0009-0003-3482-4286

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAdrenomedullin (AM) is a multifunctional peptide which under basal conditions mainly regulates vasodilation and maintains vascular integrity but is also implicated in the pathogenesis of several malignancies, including multiple myeloma (MM). It has been shown that adrenomedullin is expressed by human myeloma cell lines and that it enhances MM-driven angiogenesis. However, the clinical impact of AM remains unknown. MATERIALS AND

methodsOn that basis, we enrolled 32 newly diagnosed multiple myeloma patients (NDMM) and studied the potential of AM as a prognostic biomarker.

resultsWe report that elevated levels of AM trend with suboptimal treatment response and inferior survival of NDMM patients.

Indexed as

AdrenomedullinMultiple MyelomaNeovascularization, PathologicAgedAged, 80 and overAngiogenesisBiomarkers, TumorFemaleHumansMaleMiddle AgedPrognosisADM protein, humanAdrenomedullinBiomarkers, Tumoradrenomedullinangiogenesismultiple myelomaprognostication

Identifiers

PMID39315734
PMCPMC11420937

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.